Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Journal:
The New England Journal of Medicine
Published:
Affiliations:
5
Authors:
8
Institutions Authors Share
Peking University First Hospital, PKUHSC, China
3.000000
0.38
RemeGen, Ltd., China
2.500000
0.31
University of New South Wales (UNSW Sydney), Australia
1.000000
0.13
Vor Biopharma, United States of America (USA)
1.000000
0.13
Tongji University, China
0.500000
0.06